H5N1 News and Research

Latest H5N1 News and Research

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

...

10 Oct 2013

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

A new way to attack flu viruses is taking shape in laboratories at Rutgers University, where scientists have identified chemical agents that block the virus's ability to replicate itself in cell culture.

4 Oct 2013

Researcher characterises influenza A viruses in gulls and ducks

Ducks and gulls are the natural hosts of influenza A virus. Ragnhild Tønnessen's PhD research project has characterised influenza A viruses in gulls and ducks in Norway. Her discoveries may lead to a better understanding of the epidemiology and host adaptation of influenza A virus.

12 Sep 2013

Emerging H7N9 virus has potential to cause a pandemic

A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts.

10 Sep 2013

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

7 Sep 2013

BiondVax: Priming with universal flu vaccine makes conventional bird flu vaccine effective against pandemic strains

BiondVax announced today that priming with universal flu vaccine before boosting with a conventional bird flu H5N1 vaccine (containing a single strain from Clade 1) resulted in mice exhibiting a significantly higher level of immunity to the strain contained in the conventional bird flu vaccine and in addition, broadened immunity to other H5N1 flu strains (from Clade 2).

27 Aug 2013

Strategy that dismantles flu viral genome in human lung cells ensures safe research

A new strategy that dismantles a viral genome in human lung cells will ensure safe research on deadly strains of influenza, say researchers from the Icahn School of Medicine at Mount Sinai.

13 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

Sir Michael Stratton, Thijn Brummelkamp and Anne Glover to speak at The EMBO Meeting 2013

Predisposition to cancer and other diseases, genetic testing, infectious proteins and ubiquitin signalling -- these are some of the topics internationally renowned speakers will tackle at The EMBO Meeting 2013 to be held in Amsterdam, the Netherlands, from 21-24 September 2013.

22 Jul 2013

Some strains of avian H7N9 influenza develop resistance to antiviral drugs

Some strains of the avian H7N9 influenza that emerged in China this year have developed resistance to the only antiviral drugs available to treat the infection, but testing for antiviral resistance can give misleading results, helping hasten the spread of resistant strains.

17 Jul 2013

H7 influenza may spillover repeatedly into humans, say scientists

The H7N9 avian flu strain that emerged in China earlier this year has subsided for now, but it would be a mistake to be reassured by this apparent lull in infections. The virus has several highly unusual traits that paint a disquieting picture of a pathogen that may yet lead to a pandemic, according to lead scientists from the National Institute of Allergy and Infectious Diseases.

10 Jul 2013

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection.

6 Jul 2013

Study describes radiologic findings in H7N9 pneumonia

H7N9 pneumonia is characterized by imaging findings that differentiate it from other types of pneumonia, including rapidly progressive changes in the lungs and pulmonary connective tissues, according to the first study to describe radiologic findings in the disease. The results are published online in the journal Radiology.

2 Jul 2013

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

1 Jul 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

Medicago gets Health Canada clearance to initiate Phase II clinical trial for H5N1 vaccine

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").

11 Jun 2013

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

10 Jun 2013

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine").

6 Jun 2013

Researchers develop new gene therapy to thwart potential influenza pandemic

Researchers at the Perelman School of Medicine, University of Pennsylvania have developed a new gene therapy to thwart a potential influenza pandemic. Specifically, investigators in the Gene Therapy Program, Department of Pathology and Laboratory Medicine, directed by James M. Wilson, MD, PhD, demonstrated that a single dose of an adeno-associated virus expressing a broadly neutralizing flu antibody into the nasal passages of mice and ferrets gives them complete protection and substantial reductions in flu replication when exposed to lethal strains of H5N1 and H1N1 flu virus.

30 May 2013

H5N1 News and Research

Latest H5N1 News and Research

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

Researcher characterises influenza A viruses in gulls and ducks

Emerging H7N9 virus has potential to cause a pandemic

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

BiondVax: Priming with universal flu vaccine makes conventional bird flu vaccine effective against pandemic strains

Strategy that dismantles flu viral genome in human lung cells ensures safe research

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

Sir Michael Stratton, Thijn Brummelkamp and Anne Glover to speak at The EMBO Meeting 2013

Some strains of avian H7N9 influenza develop resistance to antiviral drugs

H7 influenza may spillover repeatedly into humans, say scientists

Seattle researchers map critical molecules that regulate inflammation during flu infection

Study describes radiologic findings in H7N9 pneumonia

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago gets Health Canada clearance to initiate Phase II clinical trial for H5N1 vaccine

NanoViricides files Orphan Drug application with FDA for DengueCide

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

Researchers develop new gene therapy to thwart potential influenza pandemic

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

H5N1 News and Research

Latest H5N1 News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in